Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome

Antiphospholipid Syndrome Clinical Trial

— MONOCYTAN  

Official title:

Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06373926
• Other study ID #: PI2019_843_0010
• Status: Recruiting
• Phase: N/A
• Start date: March 28, 2023
• Est. completion date: March 2025

Study information

• Verified date: April 2024
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: Valéry Salle, MD
• Phone: 03 22 66 82 30
• Email: salle.valery[@]chu-amiens.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Annexin A2 (ANXA2), an endothelial cell receptor for plasminogen and tissue plasminogen activator, plays a pivotal role in regulation of fibrinolysis in vitro and in vivo and has been identified as a new autoantigen in antiphospholipid syndrome (APS). ANXA2 can exist as a monomer or a heterotetrameric complex with S100A10 protein. The aim of this study was to evaluate the cell membrane expression of ANXA2 on circulating monocytes in APS by flow cytometry. Several pathogenic mechanisms are involved in APS such as activation of endothelial cells, platelets and monocytes, inhibition of the natural anticoagulant protein C/protein S pathway, activation of the complement system and also impairment of fibrinolysis. Annexin A2 which hits binding partner S100A10, ANXA2 forms a cell surface complex that regulates generation of plasmin. ANXA2 is involved in the pathogenesis of APS-associated through several possible mechanisms. Human peripheral blood monocytes represent the major circulating ANXA2-expressing cell and ANXA2-mediated assembly of plasminogen and tissue activator of plasminogen (tPA) on monocyte/macrophages contributes to plasmin generation. Thus the investigators could suppose that decrease of cell membrane expression of ANXA2 on circulating monocytes represent a new pathogenic mechanism in APS.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: March 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• APS patients who fulfilled the revised criteria for APS

Exclusion Criteria:

• Patients less than 18 years old

• Solid and hematological malignancies

• Other autoimmune diseases

• Cirrhosis

Related Conditions & MeSH terms

• Antiphospholipid Syndrome
• Syndrome

Intervention

Biological:
• blood withdrawal
blood withdrawal

Locations

Country	Name	City	State
France	CHU Amiens	Amiens

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire, Amiens

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cell membrane expression rate of ANXA2 on circulating monocytes in APS		1 hour
Secondary	Cellular expression of ANXA2 and S100A10 in APS patients		1 hour
Secondary	cell membrane expression of ANXA2 and S100A10 in APS patients		1 hour